Clinical Trial Update: Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating multiple subcutaneous doses of DiaPep277 in latent autoimmune diabetes in adults assessed safety, tolerability, immunological response,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Latent Autoimmune Diabetes in Adults

Drugs mentioned

• DiaPep277 (DiaPep277)

Snippet

Sponsor: DeveloGen Israel, Ltd. | Conditions: Diabetes, Autoimmune | Phase 2 | Status: TERMINATED